Heron Therapeutics, Inc.
HRTXNasdaqCIK 818033HealthcareFiscal year ends Dec 31
Reports and events: 405 filings
Newest first, by EDGAR acceptance time (Eastern). Each filing’s page lists its documents on sec.gov and, for 10-K and 10-Q reports, the extracted sections.
What the forms are: 10-K, 10-Q, 8-K, Form 4, DEF 14A, Schedule 13D, Schedule 13G, amendments, accession numbers.
| Filed | Form | What it is | Accession number |
|---|---|---|---|
| 2026-09-2917:00 ET | 8-K | 1.01 Entry into a material agreement; 9.01 Financial statements and exhibits | 0001193125-26-407728 |
| 2026-08-1416:30 ET | 8-K | 1.01 Entry into a material agreement; 3.03 Change to security holders’ rights; 9.01 Financial statements and exhibits | 0001193125-26-352403 |
| 2026-08-1008:00 ET | 10-Q | Quarterly reportPeriod 2026-06-30 | 0001193125-26-341301 |
| 2026-08-1008:00 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001193125-26-341300 |
| 2026-06-2517:00 ET | 8-K | 3.01 Delisting notice; 9.01 Financial statements and exhibits | 0001193125-26-282988 |
| 2026-06-1614:49 ET | 8-K | 5.07 Shareholder vote results | 0001193125-26-272388 |
| 2026-06-0217:15 ET | 8-K | 8.01 Other events; 9.01 Financial statements and exhibits | 0001193125-26-253851 |
| 2026-05-1108:00 ET | 10-Q | Quarterly reportPeriod 2026-03-31 | 0001193125-26-215755 |
| 2026-05-1108:00 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001193125-26-215752 |
| 2026-04-3014:09 ET | DEF 14A | Proxy statementPeriod 2026-04-30 | 0001193125-26-196306 |
| 2026-04-0608:30 ET | 8-K | 5.02 Departure or appointment of officers or directors; 9.01 Financial statements and exhibits | 0001193125-26-142947 |
| 2026-02-2608:06 ET | 10-K | Annual reportPeriod 2025-12-31 | 0001193125-26-073515 |
| 2026-02-2608:00 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001193125-26-073502 |
| 2026-01-0913:08 ET | 8-K | 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001193125-26-008631 |
| 2025-11-0408:00 ET | 10-Q | Quarterly reportPeriod 2025-09-30 | 0001193125-25-263618 |
| 2025-11-0408:00 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001193125-25-263617 |
| 2025-10-2916:05 ET | 8-K | 5.02 Departure or appointment of officers or directors; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001193125-25-256300 |
| 2025-10-1718:02 ET | SCHEDULE 13D/A | Ownership report, active investor, amended | 0000902664-25-004460 |
| 2025-10-1516:09 ET | 8-K | 5.07 Shareholder vote results; 9.01 Financial statements and exhibits | 0001193125-25-240253 |
| 2025-09-1916:05 ET | DEF 14A | Proxy statementPeriod 2025-10-13 | 0001193125-25-209064 |
| 2025-08-2817:02 ET | 8-K | 1.01 Entry into a material agreement; 9.01 Financial statements and exhibits | 0000950170-25-112048 |
| 2025-08-1507:45 ET | 8-K | 1.01 Entry into a material agreement; 3.03 Change to security holders’ rights; 5.03 Amendment to articles or bylaws; 8.01 Other events; 9.01 Financial statements and exhibits | 0000950170-25-109234 |
| 2025-08-1218:00 ET | SCHEDULE 13D/A | Ownership report, active investor, amended | 0000902664-25-003536 |
| 2025-08-1216:45 ET | 8-K | 1.01 Entry into a material agreement; 5.03 Amendment to articles or bylaws; 8.01 Other events; 9.01 Financial statements and exhibits | 0000950170-25-107416 |
| 2025-08-1216:35 ET | 8-K | 1.01 Entry into a material agreement | 0000950170-25-107404 |
| 2025-08-0807:45 ET | 10-Q | Quarterly reportPeriod 2025-06-30 | 0000950170-25-105475 |
| 2025-08-0807:45 ET | 8-K | 1.01 Entry into a material agreement; 2.02 Results of operations; 2.03 New direct financial obligation; 3.02 Unregistered sale of equity; 8.01 Other events; 9.01 Financial statements and exhibits | 0000950170-25-105474 |
| 2025-06-1818:17 ET | 8-K | 5.07 Shareholder vote results | 0000950170-25-087555 |
| 2025-05-0607:45 ET | 10-Q | Quarterly reportPeriod 2025-03-31 | 0000950170-25-063971 |
| 2025-05-0607:45 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0000950170-25-063973 |
| 2025-05-0607:30 ET | 8-K | 8.01 Other events; 9.01 Financial statements and exhibits | 0000950170-25-063967 |
| 2025-04-3013:52 ET | DEF 14A | Proxy statementPeriod 2025-06-12 | 0000950170-25-060882 |
| 2025-04-2918:56 ET | 8-K | 5.02 Departure or appointment of officers or directors; 9.01 Financial statements and exhibits | 0000950170-25-059479 |
| 2025-02-2707:45 ET | 10-K | Annual reportPeriod 2024-12-31 | 0000950170-25-028374 |
| 2025-02-2707:45 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0000950170-25-028372 |
| 2025-02-2013:51 ET | 8-K | 1.01 Entry into a material agreement; 9.01 Financial statements and exhibits | 0000950170-25-023958 |
| 2024-12-2316:05 ET | 8-K | 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0000950170-24-139569 |
| 2024-12-0317:15 ET | 8-K | 8.01 Other events | 0000950170-24-132874 |
| 2024-11-1208:56 ET | 10-Q | Quarterly reportPeriod 2024-09-30 | 0000950170-24-124698 |
| 2024-11-1208:06 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0000950170-24-124626 |
| 2024-11-0417:09 ET | 8-K | 5.02 Departure or appointment of officers or directors; 7.01 Regulation FD disclosure | 0000950170-24-120902 |
| 2024-08-0616:05 ET | 10-Q | Quarterly reportPeriod 2024-06-30 | 0000950170-24-091764 |
| 2024-08-0616:05 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0000950170-24-091769 |
| 2024-07-0208:44 ET | 8-K | 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0000950170-24-080026 |
| 2024-06-1816:43 ET | 8-K | 5.02 Departure or appointment of officers or directors; 5.03 Amendment to articles or bylaws; 5.07 Shareholder vote results; 9.01 Financial statements and exhibits | 0000950170-24-074952 |
| 2024-05-3111:08 ET | SC 13D/A | Ownership report, active investor, amended | 0000921895-24-001343 |
| 2024-05-2908:05 ET | 8-K | 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0000950170-24-065636 |
| 2024-05-0708:05 ET | 10-Q | Quarterly reportPeriod 2024-03-31 | 0000950170-24-053964 |
| 2024-05-0708:05 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0000950170-24-053963 |
| 2024-04-2914:33 ET | DEF 14A | Proxy statementPeriod 2024-06-13 | 0001140361-24-022881 |
Source: SEC EDGAR, the company’s filing index. Last ingested by Listed: Oct 27, 2026, 17:10 ET. Listed shows no prices and gives no investment advice.